Clinical trials: Patients with Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)
Aim of the BETAPATH study is to evaluate whether the use of a personal digital assistant (PDA) can improve the adherence of Multiple Sclerosis patients to a therapy with Betaseron.
- Trial name
- NCT00902135
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- Germany
- Volunteers
- 702 people
- Sponsor
- Bayer
Relapsing Multiple Sclerosis
A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod
A study of immune phenotype biomarkers in patients with Relapsing Multiple Sclerosis (RMS) after treatment with 0.5mg fingolimod
- Trial name
- FLUENT (NCT03257358)
- Testing
- Fingolimod
- Where
- 66 sites in United States
- Volunteers
- 382 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Walking Impairment
A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
This study assessed the long-term safety and tolerability of ADS-5102 in subjects with MS and walking impairment who had completed the double-blind, placebo-controlled study of ADS-5102 in subjects with MS (ADS-AMT-301).
- Trial name
- NCT03567057
- Testing
- ADS-5102, 274 mg
- Where
- 92 sites in United States, Canada
- Volunteers
- 424 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
Amyotrophic Lateral Sclerosis
A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
The study will generate data on safety, tolerability and pharmacokinetics after multiple daily doses of CK-2017357 in patients with ALS.
- Trial name
- NCT01378676
- Testing
- CK-2017357 (Part A), Riluzole 50 MG (Part B), CK-2017357 (Part B)
- Where
- 9 sites in United States
- Volunteers
- 49 people
- Sponsor
- Cytokinetics
Multiple Sclerosis, Relapsing-Remitting
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One
The purpose of this study was to establish the efficacy and safety of alemtuzumab (Lemtrada™) as a treatment for relapsing-remitting multiple sclerosis (MS), in comparison with subcutaneous (SC) interferon beta-1a (Rebif®).
- Trial name
- CARE-MS I (NCT00530348)
- Testing
- Alemtuzumab, Interferon beta-1a
- Where
- 101 sites in United States, Argentina and 14 more
- Volunteers
- 581 people
- Sponsor
- Genzyme, a Sanofi Company
Multiple Sclerosis, Spasticity, Muscle
A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS
Spasticity is a common complication in MS and occurs in up to 84% of patients. The main sign of spasticity is resistance to passive limb movement characterized by increased resistance to stretching, clonus, and exaggerated deep…
- Trial name
- OS440-3005 (NCT03319732)
- Testing
- Arbaclofen
- Where
- United States
- Volunteers
- 323 people
- Sponsor
- RVL Pharmaceuticals, Inc.
Multiple Sclerosis, Relapsing-Remitting
A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device
This is a randomized, comparative, and multicenter study to assess the impact of a patient support program (MinSupport Plus) on health related quality of life (HRQoL) and adherence in subjects with relapsing-remitting multiple…
- Trial name
- RebiQoL (NCT01791244)
- Testing
- Rebif®
- Where
- 14 sites in Germany, Sweden
- Volunteers
- 93 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Relapsing-Remitting
A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
The purpose of this study is to describe the reasons, therapy, and/or disease for changing first or second line Disease Modifying Therapy (DMT) to ozanimod in participants with Relapsing Remitting Multiple Sclerosis (RRMS).
- Trial name
- SWITCH - ITA (NCT05658601)
- Where
- Italy
- Volunteers
- 104 people
- Sponsor
- Bristol-Myers Squibb
Multiple Sclerosis
An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis
The primary objective of the study was to assess the effect of two doses of teriflunomide, in comparison to placebo, on the frequency of multiple sclerosis (MS) relapses in participants with relapsing MS.
- Trial name
- TOWER (NCT00751881)
- Testing
- Teriflunomide
- Where
- 193 sites in United States, Australia and 24 more
- Volunteers
- 1,169 people
- Sponsor
- Sanofi
Relapsing-Remitting Multiple Sclerosis
A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®)
This was an open-label, multicentric, prospective, post-marketing surveillance (PMS) study on the extent to which subject compliance is influenced by use of a variable titration regimen at the start of treatment of relapsing MS…
- Trial name
- TOURIMS (NCT01142492)
- Testing
- Interferon beta-1a
- Volunteers
- 403 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Relapsing-Remitting
COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS
A phase IV, observational, survey-based study to measure compliance with Avonex® PS therapy in patients with Relapsing-Remitting Multiple Sclerosis, and to compare persistence on therapy 22 months after initial prescription of…
- Trial name
- COMPASS (NCT00675883)
- Where
- Canada
- Volunteers
- 1,000 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
Adherence Trial With MS LifeLines ® Services
This is a Phase IV study to compare the current level of MS LifeLines ® (MSLL) services (face-to-face nursing visits and phone contacts) with customized MSLL services, to determine the optimal services to enhance medication…
- Trial name
- NCT01905527
- Testing
- Standard Services of Group A (Group A1), Customized Services of Group A (Group A2), Group B
- Where
- United States
- Volunteers
- 306 people
- Sponsor
- EMD Serono
Multiple Sclerosis, Relapsing-Remitting
QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea
This study is to describe the quality of life of Korean patients with early relapsing-remitting multiple sclerosis during the initial 1 year of treatment with Betaferon with several validated questionnaires.
- Trial name
- NCT01071694
- Testing
- Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046)
- Where
- South Korea
- Sponsor
- Bayer
Relapsing-remitting Multiple Sclerosis
Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS
The primary objective of this study is to determine whether combination treatment (adding methylprednisolone to Avonex) reduces progression of disability over 4 years compared to Avonex alone.
- Trial name
- NCT00168766
- Testing
- Interferon-beta-1a (Avonex) plus methylprednisolone
- Where
- 9 sites in Belgium, Denmark and 6 more
- Volunteers
- 345 people
- Sponsor
- Biogen
Multiple Sclerosis
Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis
The purpose of this study is to evaluate the activity of oral AB1010, administered at two dose levels during 3 years to patients with primary or secondary progressive multiple sclerosis.
- Trial name
- NCT01450488
- Testing
- masitinib
- Volunteers
- 35 people
- Sponsor
- AB Science
Multiple Sclerosis
Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis
The purpose of this study is to evaluate the long-term safety, tolerability and activity of Fampridine-SR in subjects with multiple sclerosis who have previously participated in either an Acorda Therapeutics or an Elan…
- Trial name
- NCT00654927
- Testing
- Fampridine-SR b.i.d. (Twice Daily)
- Where
- 22 sites in United States, Canada
- Volunteers
- 177 people
- Sponsor
- Acorda Therapeutics
Amyotrophic Lateral Sclerosis (ALS)
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS
The purpose of this study is to test the effects of PHENOGENE-1A, which is the treatment under investigation in this study. This research will investigate if PHENOGENE-1A can help people with ALS by measuring their function using…
- Trial name
- NCT07142291
- Testing
- Cromolyn Sodium (34.2 mg BID), Cromolyn Sodium (17.1 mg BID), Riluzole (100 mg)
- Where
- 22 sites in United States, Czechia and 4 more
- Volunteers
- 105 people
- Sponsor
- PhenoNet, Inc.
Relapsing-Remitting Multiple Sclerosis
An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone
This was an open-label, multicentric, prospective, post-marketing surveillance (PMS) study to investigate whether baseline treatment with high-dose interferon beta 1a (Rebif 44 μg x 3 ), administered at a high frequency, leads to…
- Trial name
- RETURN (NCT01142518)
- Testing
- Interferon beta 1a
- Volunteers
- 86 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
The objective of this study is to evaluate the safety and efficacy of ONO-4641 in patients with relapsing-remitting multiple sclerosis over a 26-week treatment period.
- Trial name
- DreaMS (NCT01081782)
- Testing
- ONO-4641
- Where
- 86 sites in United States, Belgium and 9 more
- Volunteers
- 407 people
- Sponsor
- Ono Pharma USA Inc
Amyotrophic Lateral Sclerosis, ALS
A Study to Evaluate the Safety, Efficacy, and Pharmacodynamics of PLL001 in ALS Patients
FIH, Phase 1/2, multi-centre, randomised, double-blind, placebo controlled study with an optional open-label dosing extension to assess the safety, tolerability, efficacy, and Pharmacodynamics (PD) of single or multiple (up to 48…
- Trial name
- NCT06513546
- Volunteers
- 153 people
- Sponsor
- PLL TX AUSTRALIA PTY LTD